Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.

Wu JQ, Saksena MM, Soriano V, Vispo E, Saksena NK.

Virol J. 2015 Jan 27;12:4. doi: 10.1186/s12985-014-0236-6.

2.

Relationship between endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients.

Feijoo MQ, Toro R, López Vazquez de la Torre M, Lennie V, Arce C, Moreno V, Valencia E, Vispo E, Almería C, Mangas A, Carbonero LM.

AIDS. 2014 Nov 28;28(18):2693-9. doi: 10.1097/QAD.0000000000000470.

PMID:
25493595
3.

Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.

Soriano V, Vispo E, Sierra-Enguita R, Mendoza Cd, Fernández-Montero JV, Labarga P, Barreiro P.

AIDS. 2014 Oct 23;28(16):2389-94. doi: 10.1097/QAD.0000000000000417.

PMID:
25111082
4.

Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.

Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V.

J Viral Hepat. 2014 Jul;21(7):475-9. doi: 10.1111/jvh.12180. Epub 2013 Oct 6.

PMID:
24750394
5.

Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy.

Vispo E, Barreiro P, Plaza Z, Fernández-Montero JV, Labarga P, de Mendoza C, Sierra-Enguita R, Treviño A, Lopez M, Soriano V.

AIDS. 2014 Jun 19;28(10):1473-8. doi: 10.1097/QAD.0000000000000275.

PMID:
24637541
6.

Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.

Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, Soriano V.

Clin Infect Dis. 2014 Jun;58(11):1549-53. doi: 10.1093/cid/ciu167. Epub 2014 Mar 14.

7.

Very late HCV relapse following triple therapy for hepatitis C.

Barreiro P, Vispo E, Maida I, Aguilera A, Fernández-Montero JV, de Mendoza C, Labarga P, Soriano V.

Antivir Ther. 2014;19(7):723-4. doi: 10.3851/IMP2753. Epub 2014 Feb 17. No abstract available.

PMID:
24535551
8.

Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection.

Gupta P, Liu B, Wu JQ, Soriano V, Vispo E, Carroll AP, Goldie BJ, Cairns MJ, Saksena NK.

Virology. 2014 Feb;450-451:336-49. doi: 10.1016/j.virol.2013.12.026. Epub 2014 Jan 14.

9.

Emerging antiretroviral drugs.

Fernández-Montero JV, Vispo E, Soriano V.

Expert Opin Pharmacother. 2014 Feb;15(2):211-9. doi: 10.1517/14656566.2014.863277. Epub 2013 Nov 30. Review.

PMID:
24289800
10.

Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.

Fernández-Montero JV, Barreiro P, Vispo E, Labarga P, Sánchez-Parra C, de Mendoza C, Treviño A, Soriano V.

Antivir Ther. 2014;19(3):287-92. doi: 10.3851/IMP2703. Epub 2013 Nov 5.

PMID:
24192598
11.

Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy.

Barreiro P, Labarga P, Fernández-Montero JV, Poveda E, de Mendoza C, Sánchez C, Vispo E, Soriano V.

J Clin Virol. 2013 Oct;58(2):391-5. doi: 10.1016/j.jcv.2013.06.031. Epub 2013 Jul 30.

PMID:
23910933
12.

Hepatitis B in HIV-infected patients.

Soriano V, Poveda E, Vispo E, Barreiro P.

Clin Liver Dis. 2013 Aug;17(3):489-501. doi: 10.1016/j.cld.2013.05.008. Epub 2013 Jul 8. Review.

PMID:
23905818
13.

Update on HIV/HCV coinfection.

Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P.

Curr HIV/AIDS Rep. 2013 Sep;10(3):226-34. doi: 10.1007/s11904-013-0169-5. Review.

PMID:
23832718
14.

Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.

Soriano V, Vispo E, de Mendoza C, Labarga P, Plaza Z, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P.

Antivir Ther. 2013;18(8):1033-5. doi: 10.3851/IMP2659. Epub 2013 Jun 27.

PMID:
23804629
15.

Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.

Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V.

AIDS. 2013 Apr 24;27(7):1187-8. doi: 10.1097/QAD.0b013e32835cb815.

PMID:
23739226
16.

Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain.

Sánchez C, Plaza Z, Vispo E, de Mendoza C, Barreiro P, Fernández-Montero JV, Labarga P, Poveda E, Soriano V.

Liver Int. 2013 Oct;33(9):1357-62. doi: 10.1111/liv.12212. Epub 2013 Jun 3.

PMID:
23730876
17.

Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.

Plaza Z, Aguilera A, Mena A, Vispo E, Sierra-Enguita R, Tomé S, Pedreira J, Rodriguez C, Barreiro P, del Romero J, Soriano V, Poveda E.

AIDS. 2013 Sep 10;27(14):2219-24. doi: 10.1097/QAD.0b013e328362fe42.

PMID:
23669158
18.

Hepatitis C therapy with HCV NS5B polymerase inhibitors.

Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, Treviño A, Barreiro P.

Expert Opin Pharmacother. 2013 Jun;14(9):1161-70. doi: 10.1517/14656566.2013.795543. Epub 2013 Apr 27. Review.

PMID:
23621117
19.

Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients.

Vispo E, Cevik M, Rockstroh JK, Barreiro P, Nelson M, Scourfield A, Boesecke C, Wasmuth JC, Soriano V; European Network of Clinical Trials (NEAT).

Clin Infect Dis. 2013 Apr;56(8):1117-22. doi: 10.1093/cid/cit001. Epub 2013 Jan 11.

20.

Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.

Fernández-Montero JV, Barreiro P, Vispo E, Labarga P, Sánchez-Parra C, Soriano V.

AIDS. 2013 Apr 24;27(7):1129-34. doi: 10.1097/QAD.0b013e32835e063f.

PMID:
23276803
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk